TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9690695

Group type: EXPERIMENTAL
Intervention: ziprasidone 160 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: haloperidol 15 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ziprasidone 4 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ziprasidone 10 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ziprasidone 40 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ziprasidone 160 mg/day and haloperidol 15 mg/day
Number of subjects: 90
Study: 8081430

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (pI)
Number of subjects: 48
Study: 2568105

Group type: EXPERIMENTAL
Intervention: Beta 2 sympathomimetic drugs administered by aerosol inhaler
Number of subjects: 100

Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 100
Study: 29514693

Group type: EXPERIMENTAL
Intervention: 2 × 10^6/kg human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein before transplantation and 5 × 10^6 cells via renal artery during surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard induction therapy (non-MSC treatment)
Number of subjects: 42
Study: 28246891

Group type: EXPERIMENTAL
Intervention: Active tDCS (anode F3 and cathode F4, 2 mA intensity, 30 min/day)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 152
Study: 25651922

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 9324
Study: 23508603

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care testing
Number of subjects: 379

Group type: COMPARATOR
Intervention: No CRP point-of-care testing (Control)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 379

Group type: COMPARATOR
Intervention: No communication skills training (Control)
Number of subjects: 379
Study: 21439529

Group type: EXPERIMENTAL
Intervention: Combination therapy with ezetimibe 10 mg/day and atorvastatin 40 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day and placebo (monotherapy group)
Number of subjects: 100
Study: 18974446

Group type: EXPERIMENTAL
Intervention: Exercise interventions for prevention of falls and sarcopenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum vitamin D concentration
Number of subjects: 0
Study: 17138156

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with propofol (4 mg/kg per hour)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with midazolam (0.2 mg/kg per hour)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with nitrous oxide (30% inhalation)
Number of subjects: 9
Study: 14562489

Group type: EXPERIMENTAL
Intervention: School-based, nurse-facilitated support group (met twice weekly for 4 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study: 10781117

Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clinician-controlled propofol sedation
Number of subjects: 18
Study: 8776195

Group type: EXPERIMENTAL
Intervention: Experimental design approach using a combination of solution concentration, air exchange rate, and body type in a cross-classified design for estimating historical exposures to formaldehyde.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Statistical models based on available exposure data.
Number of subjects: 25
Study: 1731596

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Rifampin for 12 wk (R3)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Isoniazid and rifampin for 12 wk (HR3)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Isoniazid alone for 24 wk (H6)
Number of subjects: 679
Study: 6150888

Group type: EXPERIMENTAL
Intervention: SST-14 (3.5 microgram kg‐1 h‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (0.14, 0.28, 0.56, or 1.12 microgram kg‐1 h‐1)
Number of subjects: 10
Study: 31842674

Group type: EXPERIMENTAL
Intervention: Percutaneous antegrade flexible intramedullary nailing (Group I)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Crossed Kirschner-wires (Group II)
Number of subjects: 46
Study: 28960486

Group type: EXPERIMENTAL
Intervention: GP2015 (etanercept biosimilar)
Number of subjects: 531

Group type: COMPARATOR
Intervention: ETN (Enbrel®)
Number of subjects: 531
Study: 27297245

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard medical treatment only
Number of subjects: 213
Study: 25035783

Group type: EXPERIMENTAL
Intervention: Radical FESS (RFESS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conservative FESS (CFESS)
Number of subjects: 60
Study: 23512415

Group type: COMPARATOR
Intervention: Regular Human Insulin (RHI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IA)
Number of subjects: 29
Study: 19838618

Group type: EXPERIMENTAL
Intervention: Low-fat milk fermented by S. thermophilus and Lactobacillus casei, with Lactobacillus acidophilus, oligofructose and inulin added after fermentation (test product)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Low-fat milk fermented by S. thermophilus (control product)
Number of subjects: 162
Study: 18380741

Group type: EXPERIMENTAL
Intervention: Sitz bath (twice-daily) along with antibiotics and analgesics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (antibiotics and analgesics alone)
Number of subjects: 50
Study: 16618974

Group type: EXPERIMENTAL
Intervention: cookie test
Number of subjects: 64

Group type: COMPARATOR
Intervention: liquid glucose
Number of subjects: 64
Study: 15375790

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Glyburide (10 mg)
Number of subjects: 27
Study: 11352951

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 907

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 907
Study: 9221851

Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior resection (LAR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open anterior resection (OAR)
Number of subjects: 40
Study: 8244838

Group type: EXPERIMENTAL
Intervention: Self-paced key press with attention on movement (Part 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discrimination of two tones triggered by key press (Part 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Post-movement potential after negative RP
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: N100 response to tone after positive RPs
Number of subjects: 16
Study: 3629205

Group type: EXPERIMENTAL
Intervention: Soft-laser therapy (He-Ne laser, 6 J/cm2, 9 treatments)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham irradiation (control group)
Number of subjects: 17
Study: 29289583

Group type: EXPERIMENTAL
Intervention: Usual care plus standing balance circuit classes (1-hour class, 3 times a week for 2 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 162
Study: 27662442

Group type: EXPERIMENTAL
Intervention: Health communication intervention (specifics not provided)
Number of subjects: 410
Study: 25632085

Group type: EXPERIMENTAL
Intervention: Fingolimod (mean exposure to study drug, 2.4 years)
Number of subjects: 3635
Study: 21396848

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5 g 2.5%) 20 minutes before TPB
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lidocaine-ketorolac gel (5 g 2.5% lidocaine + 0.3% ketorolac tromethamine) 1 hour before TPB
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (5 g 2.5%) 10 minutes before TPB
Number of subjects: 300
Study: 20872196

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy + resection + adjuvant therapy with imatinib
Number of subjects: 41

Group type: COMPARATOR
Intervention: Imatinib alone
Number of subjects: 41
Study: 18212624

Group type: EXPERIMENTAL
Intervention: Left-sided HALDN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right-sided HALDN
Number of subjects: 60
Study: 17022854

Group type: EXPERIMENTAL
Intervention: IV paracetamol 1 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV dipyrone 1 g
Number of subjects: 40
Study: 15053490

Group type: EXPERIMENTAL
Intervention: Massage therapy for 20 minutes twice per week over the course of one month
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study: 10049409

Group type: EXPERIMENTAL
Intervention: Transnasal route with 6.0 mm diameter pediatric videoendoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral route with 6.0 mm diameter standard videoendoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral route with 6.0 mm diameter pediatric videoendoscope
Number of subjects: 100
Study: 7783058

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 2169784

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg; n = 114) administered as a 5 min infusion, with two additional 40 micrograms/kg doses allowed
Number of subjects: 234

Group type: COMPARATOR
Intervention: High-dose metoclopramide plus dexamethasone (120 patients) - Dexamethasone 12 mg intravenously over 30 min, followed by a loading dose of 3 mg/kg metoclopramide, then maintenance dose of 4 mg/kg over 8 h
Number of subjects: 234
Study: 6991106

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU‐cyclophosphamide‐prednisone (group A)
Number of subjects: 139

Group type: COMPARATOR
Intervention: melphalan‐prednisone (group B)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: good response patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: partial response patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: no response patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: stage I patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: stage II patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: stage III patients
Number of subjects: 139
Study: 31983056

Group type: EXPERIMENTAL
Intervention: Secukinumab (300 or 150 mg)
Number of subjects: 858

Group type: COMPARATOR
Intervention: SDZ-ADL (40 mg)
Number of subjects: 858
Study: 29973755

Group type: EXPERIMENTAL
Intervention: Popsicle
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Popsicle (whole vs partially eaten)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no popsicle)
Number of subjects: 109
Study: 27835037

Group type: EXPERIMENTAL
Intervention: Android‐HCLS
Number of subjects: 28

Group type: COMPARATOR
Intervention: SAP‐LGS
Number of subjects: 28
Study: 24604234

Group type: EXPERIMENTAL
Intervention: PGL2001 (E2MATE) at 4 mg/week
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PGL2001 (E2MATE) + NETA
Number of subjects: 24
Study: 23496302

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 481

Group type: COMPARATOR
Intervention: Multiple daily injections + self monitoring of blood glucose
Number of subjects: 481
Study: 21322181

Group type: EXPERIMENTAL
Intervention: sirdalud MR (tizanidine modified release) 6 mg per day
Number of subjects: 54

Group type: COMPARATOR
Intervention: sirdalud (standard form of tizanidine) 2 mg 3 times daily
Number of subjects: 54
Study: 18504443

Group type: EXPERIMENTAL
Intervention: Accumulated exercise (ten 3‐min bouts of cycling at 60% of maximum heart rate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous exercise (one 30‐min bout of cycling at 60% of maximum heart rate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study: 16637392

Group type: EXPERIMENTAL
Intervention: Revascularization surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 20
Study: 14695409

Group type: COMPARATOR
Intervention: Single autologous stem-cell transplantation
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Double autologous stem-cell transplantation
Number of subjects: 399
Study: 10532497

Group type: EXPERIMENTAL
Intervention: Peer education program for children with asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline allergen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mold levels
Number of subjects: 0
Study: 8712161

Group type: EXPERIMENTAL
Intervention: Elbow supported on a table
Number of subjects: 32

Group type: COMPARATOR
Intervention: Elbow unsupported
Number of subjects: 32
Study: 1932485

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7084076

Group type: EXPERIMENTAL
Intervention: Sequential compression prophylaxis with 90-100 mm Hg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sequential compression with 35 mm Hg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heparin 5000 units three times daily
Number of subjects: 25
Study: 3909420

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megestrol acetate (Megace)
Number of subjects: 0
Study: 28655066

Group type: EXPERIMENTAL
Intervention: Uniportal video-assisted thoracoscopic surgery (UVATS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Classical VATS
Number of subjects: 126
Study: 27302101

Group type: EXPERIMENTAL
Intervention: Peer coaching
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 18
Study: 24856940

Group type: EXPERIMENTAL
Intervention: Circuit class therapy sessions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Individual therapy sessions
Number of subjects: 29
Study: 22431712

Group type: EXPERIMENTAL
Intervention: Microneedle device applied to facial skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham device applied to facial skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microneedle device vs Sham device
Number of subjects: 0
Study: 20128831

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling with chlorhexidine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Full-mouth scaling without chlorhexidine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both treatment modalities
Number of subjects: 13
Study: 18606271

Group type: EXPERIMENTAL
Intervention: Immersive, interactive virtual pedestrian environment
Number of subjects: 176
Study: 15834602

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) measurements
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) measurements with six input parameters
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) measurements with fifteen input parameters
Number of subjects: 124
Study: 11936567

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) with high-fat meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) with light meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) with yogurt
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) with applesauce
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) 1 hour before light meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) 2 hours after light meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) 1.5 hours before meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) 2 hours before meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg) 3 hours before meal
Number of subjects: 20
Study: 10631409

Group type: COMPARATOR
Intervention: NSAIDs (diclofenac, ketorolac, indomethacin, ibuprofen) used for up to three days after surgery
Number of subjects: 345

Group type: COMPARATOR
Intervention: NSAIDs (diclofenac, ketorolac, indomethacin, ibuprofen)
Number of subjects: 345
Study: 7481419

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amitriptyline (150 mg)
Number of subjects: 40
Study: 2251492

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 33
Study: 7005796

Group type: EXPERIMENTAL
Intervention: Scheie procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 15
Study: 30717634

Group type: EXPERIMENTAL
Intervention: 1 × 30 s
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 × 10 s
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 × 10 s
Number of subjects: 36
Study: 29155000

Group type: EXPERIMENTAL
Intervention: Cerebrolysin for 4 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 192
Study: 27478346

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) administered to a targeted dorsal root ganglion (DRG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection (TFESI)
Number of subjects: 44
Study: 25148570

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 784

Group type: COMPARATOR
Intervention: Acarbose and Metformin
Number of subjects: 784
Study: 23271771

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731

Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 731
Study: 19723990

Group type: EXPERIMENTAL
Intervention: Intention-to-treat principle used
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Strict adherence to intention-to-treat principle
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Exclusion of patients lost to follow-up
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Method of adjusting for missing data
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Yearly increase in use of intention-to-treat principle
Number of subjects: 274
Study: 17149715

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15043665

Group type: EXPERIMENTAL
Intervention: Caudal block with 0.25% bupivacaine 2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no caudal block)
Number of subjects: 30
Study: 11011333

Group type: EXPERIMENTAL
Intervention: Abciximab therapy
Number of subjects: 1472
Study: 9407413

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once a day, N = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (N = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once a day)
Number of subjects: 22
Study: 8350339

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg per os once daily (po od)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Diclofenac (Voltaren) 50 mg per os 3 times a day (po tid)
Number of subjects: 98
Study: 3491533

Group type: EXPERIMENTAL
Intervention: Calcium-supplemented (1.5 g)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (NS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 99
Study: 31903657

Group type: EXPERIMENTAL
Intervention: Methotrexate plus cetuximab
Number of subjects: 45

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 45
Study: 30829524

Group type: EXPERIMENTAL
Intervention: Revealing both successes and failures encountered on the path to success
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning about the failures of a successful entrepreneur
Number of subjects: 0
Study: 28479175

Group type: EXPERIMENTAL
Intervention: PCV13 formulated with 2-phenoxyethanol in multidose vials (MDV)
Number of subjects: 500

Group type: COMPARATOR
Intervention: PCV13 without 2-phenoxyethanol in single-dose syringe (SDS)
Number of subjects: 500
Study: 25978746

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-BF)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 154
Study: 23188186

Group type: EXPERIMENTAL
Intervention: RapidArc (RA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional Intensity‐Modulated Radiation Therapy (IMRT)
Number of subjects: 8
Study: 21242555

Group type: EXPERIMENTAL
Intervention: Automated family history assessment and tailored messages for coronary heart disease, stroke, diabetes, colorectal, breast, and ovarian cancer.
Number of subjects: 4248

Group type: COMPARATOR
Intervention: Standard preventive message related to lifestyle and screening (control group).
Number of subjects: 4248
Study: 18814274

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 300
Study: 16834834

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 12719393

Group type: EXPERIMENTAL
Intervention: Low field strength magnetic resonance imaging (MRI)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ultrasound imaging
Number of subjects: 134
Study: 10770814

Group type: EXPERIMENTAL
Intervention: Elective antibiotic treatment (4 treatments per year)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Symptomatic antibiotic treatment (3 treatments per year)
Number of subjects: 60
Study: 9132691

Group type: EXPERIMENTAL
Intervention: Memantine (30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8419210

Group type: EXPERIMENTAL
Intervention: 3.6 mM pentoxifylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without pentoxifylline)
Number of subjects: 0
Study: 3721670

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide cream (0.1%) applied daily for 14 days under occlusion.
Number of subjects: 10
Study: 31934777

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser followed by CPP-ACP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no preventive measures)
Number of subjects: 80